nach oben

Strahlentherapie und Onkologie

Erschienen in:

02.03.2023 | Case Study

Stereotactic ablative radiotherapy for unresectable inferior vena cava tumor thrombus in a patient with renal cell carcinoma: a case report

verfasst von: Pauline Castelnau-Marchand, Nathaniel Scher, Marc Bollet, Cyrus Chargari, Alain Toledano

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Treatment options for renal cell carcinoma (RCC) with inferior vena cava tumor thrombus (IVC-TT) are limited and carry substantial risks. Currently, there are no standard treatment options in the setting of recurrent or unresectable RCC with IVC-TT.

Methods

We report our experience of treating an IVC-TT RCC patient with stereotactic body radiation therapy (SBRT).

Results

This 62-year-old gentleman presented renal cell carcinoma with IVC-TT and liver metastases. Initial treatment consisted of radical nephrectomy and thrombectomy followed by continuous sunitinib. At 3 months, he developed an unresectable IVC-TT recurrence. A fiducial marker was implanted into the IVC-TT by catheterization. New biopsies were performed at the same time, demonstrating a recurrence of the RCC. SBRT consisted of 5 fractions of 7 Gy to the IVC-TT with excellent initial tolerance. He subsequently received anti-PD1 therapy (nivolumab). At 4 years follow-up, he is doing well with no IVC-TT recurrence and no late toxicity.

Conclusion

SBRT appears to be a feasible and safe treatment for IVC-TT secondary to RCC in patients who are not candidates for surgery.

Linehan WM, Walther MM, Zbar B (2003) The genetic basis of cancer of the kidney. J Urol 170:2163–2172CrossRefPubMed

Rabinovitch RA, Zelefsky MJ, Gaynor JJ, Fuks Z (1994) Patterns of failure following surgical resection of renal cell carcinoma: Implications for adjuvant local and systemic therapy. J Clin Oncol 12:206–212CrossRefPubMed

Cozad SC, Smalley SR, Austenfeld M, Noble M, Jennings S, Raymond R (1995) Transitional cell carcinoma of the renal pelvis or ureter: patterns of failure. Urology 46:796–800CrossRefPubMed

Motzer RJ, Tannir NM, McDermott DF, Frontera AO, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S et al (2018) Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378:1277–1290CrossRefPubMedPubMedCentral

Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1116–1127CrossRefPubMed

Freifeld Y, Woldu SL, Singla N, Clinton T, Bagrodia A, Hutchinson R et al (2019) Impact of hospital case volume on outcomes following radical nephrectomy and inferior vena cava thrombectomy. Eur Urol Oncol 2(6):691–698CrossRefPubMed

Motzer RJ, Bukowski RM, Szczylik C, Baum CM (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. https://doi.org/10.1056/NEJMoa065044CrossRefPubMed

Adams LC, Ralla B, Bender Y‑NY, Bressem K, Hamm B, Busch J et al (2018) Renal cell carcinoma with venous extension: prediction of inferior vena cava wall invasion by MRI. Cancer Imaging 18(1):17–13CrossRefPubMedPubMedCentral

Nini A, Capitanio U, Larcher A, Dell’Oglio P, Dehò F, Suardi N et al (2018) Perioperative and oncologic outcomes of nephrectomy and caval thrombectomy using extracorporeal circulation and deep hypothermic circulatory arrest for renal cell carcinoma invading the Supradiaphragmatic inferior Vena Cava and/or right atrium. Eur Urol 73(5):793–799CrossRefPubMed

10.

Wang CJ, Christie A, Lin M‑H, Jung M, Weix D, Huelsmann L et al (2017) Safety and efficacy of stereotactic ablative radiation therapy for renal cell carcinoma extracranial metastases. Int J Radiat Oncol Biol Phys 98(1):91–100CrossRefPubMedPubMedCentral

11.

Margulis V, Freifeld Y, Pop LM, Manna S, Kapur P, Pedrosa I et al (2021) Neoadjuvant SABR for renal cell carcinoma inferior vena cava tumor thrombus-safety lead-in results of a phase 2 trial. Int J Radiat Oncol Biol Phys. https://doi.org/10.1016/j.ijrobp.2021.01.054CrossRefPubMedPubMedCentral

12.

Hou J‑Z, Zeng Z‑C, Zhang J‑Y, Fan J, Zhou J, Zeng M‑S (2012) Influence of tumor thrombus location on the outcome of external-beam radiation therapy in advanced hepatocellular carcinoma with macrovascular invasion. Int J Radiat Oncol Biol Phys 84(2):362–368CrossRefPubMed

13.

Haddad AQ, Leibovich BC, Abel EJ, Luo J‑H, Krabbe L‑M, Thompson RH, Heckman JE, Merrill MM, Gayed BA, Sagalowsky AI et al (2015) Preoperative multivariable prognostic models for prediction of survival and major complications following surgical resection of renal cell carcinoma with suprahepatic caval tumor thrombus. Urol Oncol Semin Orig Investig 33:388.e1–388.e9

14.

Stanic S, Paulus R, Timmerman RD, Michalski JM, Barriger RB, Bezjak A, Videtic GM, Bradley J (2014) No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early-stage peripheral non-small cell lung cancer: an analysis of RTOG 0236. Int J Radiat Oncol 88:1092–1099CrossRef

15.

Timmerman R (2022) A Story of Hypofractionation and the Table on the Wall. Int J Radiat Oncol Biol Phys. 2022 Jan 1;112(1):4–21. https://doi.org/10.1016/j.ijrobp.2021.09.027. PMID: 34919882.

16.

Boike TP, Lotan Y, Cho LC, Brindle J, Derose P, Xie X‑J, Yan J, Foster R, Pistenmaa D, Perkins A et al (2011) Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol 29:2020–2026CrossRefPubMedPubMedCentral

17.

Ryu S, Pugh SL, Gerszten PC, Yin F‑F, Timmerman RD, Hitchcock YJ, Movsas B, Kanner AA, Berk LB, Followill DS et al (2014) RTOG 0631 phase 2/3 study of image guided stereotactic radiosurgery for localized (1–3) spine metastases: phase 2 results. Pract Radiat Oncol 4:76–81CrossRefPubMed

18.

Ning S, Trisler K, Wessels BW, Knox SJ (1997) Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer 80:2519–2528CrossRefPubMed

19.

Walsh L, Stanfield JL, Cho LC, Chang CH, Forster K, Kabbani W, Cadeddu JA, Hsieh JT, Choy H, Timmerman R et al (2006) Efficacy of ablative high-dose-per-fraction radiation for implanted human renal cell cancer in a nude mouse model. Eur Urol 50:795–800CrossRefPubMed

20.

De Meerleer G, Khoo V, Escudier B, Joniau S, Bossi A, Ost P, Briganti A, Fonteyne V, Van Vulpen M, Lumen N et al (2014) Radiotherapy for renal-cell carcinoma. Lancet Oncol 15:e170–e177CrossRefPubMed

21.

Xi M, Zhang L, Zhao L, Li Q‑Q, Guo S‑P, Feng Z‑Z et al (2013) Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis. Plos One 8(5):e63864CrossRefPubMedPubMedCentral

22.

Matsuo Y, Yoshida K, Nishimura H, Ejima Y, Miyawaki D, Uezono H et al (2016) Efficacy of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis/inferior vena cava tumor thrombosis: evaluation by comparison with conventional three-dimensional conformal radiotherapy. J Radiat Res. https://doi.org/10.1093/jrr/rrw028CrossRefPubMedPubMedCentral

23.

Shui Y, Yu W, Ren X, Guo Y, Xu J, Ma T et al (2018) Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis. Radiat Oncol 13(1):188CrossRefPubMedPubMedCentral

24.

Deutsch E, Chargari C, Galluzzi L, Kroemer G (2019) Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy. Lancet Oncol 20(8):e452–e463CrossRefPubMed

25.

Freifeld Y, Pedrosa I, Mclaughlin M, Correa RM, Louie AV, Maldonado JA, Tang C, Kadow B, Kutikov A, Uzzo RG et al (2022) Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus. Urol Oncol Semin Orig Investig 40:166.e9–166.e13

Titel: Stereotactic ablative radiotherapy for unresectable inferior vena cava tumor thrombus in a patient with renal cell carcinoma: a case report
verfasst von: Pauline Castelnau-Marchand
Nathaniel Scher
Marc Bollet
Cyrus Chargari
Alain Toledano
Publikationsdatum: 02.03.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 4/2023
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-023-02054-0

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Stereotactic ablative radiotherapy for unresectable inferior vena cava tumor thrombus in a patient with renal cell carcinoma: a case report

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2023

Organerhaltende Therapie des muskelinvasiven Blasenkarzinoms: 10-Jahres-Daten der britischen BC2001-Studie

Development, implementation, and results of a simulation-based hands-on brachytherapy workshop for medical students

Teaching in radiation oncology: now and 2025—results of a focus group with medical students

Sekundärmalignome nach Ganzkörperbestrahlung bei pädiatrischer ALL

Automatic planning of the lower extremities for total marrow irradiation using volumetric modulated arc therapy

Deep inspiration breath-hold radiation therapy in left-sided breast cancer patients: a single-institution retrospective dosimetric analysis of organs at risk doses

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie